Shakun Karki, PhD
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Cardiovascular Medicine

PhD, Boston University School of Medicine

Obesity represents the largest preventable health care problem in the United States. More than two third of deaths related to obesity worldwide are from cardiovascular cause. Pathological mechanisms that connect obesity with cardiovascular are incompletely understood. Dr. Karki's research interests focuses on understanding the mechanisms of obesity induced diseases, including endothelial and vascular dysfunction, insulin-resistance and cardiovascular disease.

2018-2022 NIH/National Institute of Diabetes and Digestive and Kidney Diseases : FSP27 regulation of vascular function in human obesity.
2017 Boston University School of Medicine: Faculty Development Diversity Grant
2014 Boston University Medical School: Evans Day-Best Clinical Research, Runner up
2013 Postdoctoral: Whitaker Cardiovascular Institute, Boston University: T32 HL07224
2011-2012 Training Cardiovascular Biology: Predoctoral: 5T32HL007969-02
2001-2001 University of New Hampshire: Summer Teaching Fellow

FSP27 regulation of vascular function in human obesity
07/01/2018 - 06/30/2022 (PI)
NIH/National Diabetes & Digestive & Kidney Diseases

Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Ngo DTM, Sverdlov AL, Karki S, Macartney-Coxson D, Stubbs RS, Farb MG, Carmine B, Hess DT, Colucci WS, Gokce N. Oxidative modifications of mitochondrial complex II are associated with insulin resistance of visceral fat in obesity. Am J Physiol Endocrinol Metab. 2019 Feb 01; 316(2):E168-E177.View Related Profiles. PMID: 30576243.
  2. Zuriaga MA, Fuster JJ, Farb MG, MacLauchlan S, Bretón-Romero R, Karki S, Hess DT, Apovian CM, Hamburg NM, Gokce N, Walsh K. Activation of non-canonical WNT signaling in human visceral adipose tissue contributes to local and systemic inflammation. Sci Rep. 2017 Dec 11; 7(1):17326.View Related Profiles. PMID: 29229927; DOI: 10.1038/s41598-017-17509-5;.
  3. Farb MG, Park SY, Karki S, Gokce N. Assessment of Human Adipose Tissue Microvascular Function Using Videomicroscopy. J Vis Exp. 2017 Sep 29; (127).View Related Profiles. PMID: 28994775.
  4. Karki S, Ngo DTM, Farb MG, Park SY, Saggese SM, Hamburg NM, Carmine B, Hess DT, Walsh K, Gokce N. WNT5A regulates adipose tissue angiogenesis via antiangiogenic VEGF-A165b in obese humans. Am J Physiol Heart Circ Physiol. 2017 Jul 01; 313(1):H200-H206.View Related Profiles. PMID: 28411232; DOI: 10.1152/ajpheart.00776.2016;.
  5. Farb MG, Karki S, Park SY, Saggese SM, Carmine B, Hess DT, Apovian C, Fetterman JL, Bretón-Romero R, Hamburg NM, Fuster JJ, Zuriaga MA, Walsh K, Gokce N. WNT5A-JNK regulation of vascular insulin resistance in human obesity. Vasc Med. 2016 Dec; 21(6):489-496.View Related Profiles. PMID: 27688298.
  6. Karki S, Farb MG, Myers S, Apovian C, Hess DT, Gokce N. Effect of Bariatric Weight Loss on the Adipose Lipolytic Transcriptome in Obese Humans. Mediators Inflamm. 2015; 2015:106237.View Related Profiles. PMID: 26663986; DOI: 10.1155/2015/106237;.
  7. Karki S, Farb MG, Ngo DT, Myers S, Puri V, Hamburg NM, Carmine B, Hess DT, Gokce N. Forkhead box O-1 modulation improves endothelial insulin resistance in human obesity. Arterioscler Thromb Vasc Biol. 2015 Jun; 35(6):1498-506.View Related Profiles. PMID: 25908760; PMCID: PMC4441602; DOI: 10.1161/ATVBAHA.114.305139;.
  8. Ngo DT, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, Bates DO, LaValley MP, Hamburg NM, Vita JA, Hess DT, Walsh K, Gokce N. Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation. 2014 Sep 23; 130(13):1072-80.View Related Profiles. PMID: 25116954; PMCID: PMC4175289; DOI: 10.1161/CIRCULATIONAHA.113.008171;.
  9. Karki S, Ngo DT, Bigornia SJ, Farb MG, Gokce N. Insulin resistance: a key therapeutic target for cardiovascular risk reduction in obese patients? Expert Rev Endocrinol Metab. 2014 Mar; 9(2):93-95.View Related Profiles. PMID: 30743752.
  10. Karki S, Ngo DT, Bigornia S, Farb MG, Gokce N. . Exp Rev Endo & Metab. Insulin resistance: A key therapeutic target for cardiovascular risk reduction in obese patients. 2014.
Showing 10 of 16 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 16 publications over 8 distinct years, with a maximum of 3 publications in 2013 and 2014 and 2017

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Obesity, endothelial andvascular dysfunction, insulin-resistance, type 2 diabetes, CVD
Contact for Mentoring:

72 E. Concord St Evans Building
Boston MA 02118
Google Map

Karki's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department